Observation versus adjuvant radiation or chemotherapy in the management of stage i seminoma: Clinical outcomes and prognostic factors for relapse in a large us cohort

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 37, Issue 4, 2014, Pages 356-359

  Soper, Margaret S ^a   Hastings, Joseph R ^a   Cosmatos, Harry A ^a   Slezak, Jeffrey M ^b   Wang, Ricardo ^a   Lodin, Kenneth ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

Adjuvant; Chemotherapy; Neoplasm recurrence; Radiotherapy; Seminoma; Testicular neoplasms

Indexed keywords

ADULT; CALIFORNIA; CHEMOTHERAPY, ADJUVANT; CHORIONIC GONADOTROPIN; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; ORCHIECTOMY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SEMINOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 84905107175     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318277d839     Document Type: Article

References (16)

1. Warde P, Sturgeon JF, Gospodarowicz MK. Testicular cancer. In: Gunderson LL, Tepper JE, eds. Clinical Radiation Oncology. 2nd ed. Philadelphia, PA: Churchill Livingstone; 2007: 1261-1285.
2. Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997; 89: 1429-1439.
3. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40, 576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005; 97: 1354-1365.
4. Horwich A, Alsanjari N, A'Hern R, et al. Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer. 1992; 65: 775-778.
5. Von der Maase H, Specht L, Jacobsen GK, et al. Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer. 1993; 29A: 1931-1934.
6. Warde P, Gospodarowicz MK, Banerjee D, et al. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol. 1997; 157: 1705-1709; discussion 1709-10.
7. Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. APMIS. 2003; 111: 76-83; discussion 83-85.
8. Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002; 20: 4448-4452.
9. Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005; 366: 293-300.
10. Oliver RT, Mead GM, Rustin GJ, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011; 29: 957-962.
11. Oliver RT, Edmonds PM, Ong JY, et al. Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy? Int J Radiat Oncol Biol Phys. 1994; 29: 3-8.
12. Mead GM, Fossa SD, Oliver RT, et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst. 2011; 103: 241-249.
13. Chung P, Parker C, Panzarella T, et al. Surveillance in stage I testicular seminoma-risk of late relapse. Can J Urol. 2002; 9: 1637-1640.
14. Choo R, Thomas G, Woo T, et al. Long-term outcome of postorchiectomy surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys. 2005; 61: 736-740.
15. Aparicio J, Germa JR, Garcia del Muro X, et al. Risk-adapted management for patients with clinical stage I seminoma: the second Spanish germ cell cancer cooperative group study. J Clin Oncol. 2005; 23: 8717-8723.
16. Chung PW, Daugaard G, Tyldesley S, et al. Prognostic factors for relapse in stage I seminoma managed with surveillance: a validation study. J Clin Oncol. 2010; 28(suppl): 15s, abstr 4535.